Identification

Name
Papaverine
Accession Number
DB01113  (APRD00628, DB07725)
Type
Small Molecule
Groups
Approved
Description

An alkaloid found in opium but not closely related to the other opium alkaloids in its structure or pharmacological actions. It is a direct-acting smooth muscle relaxant used in the treatment of impotence and as a vasodilator, especially for cerebral vasodilation. The mechanism of its pharmacological actions is not clear, but it apparently can inhibit phosphodiesterases and it may have direct actions on calcium channels. [PubChem]

Structure
Thumb
Synonyms
  • Mesotina
Product Ingredients
IngredientUNIICASInChI Key
Papaverine Codecarboxylate3RX65N0VN756896-69-6VTJFMXLVZKZSGE-UHFFFAOYSA-N
Papaverine Hydrochloride23473EC6BQ61-25-6UOTMYNBWXDUBNX-UHFFFAOYSA-N
Papaverine sulfate7A476JZB2T2053-26-1KYFCEOITJFJQGT-UHFFFAOYSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Papaverine Hydrochloride Injection USPLiquid65 mgIntramuscular; Intravenous; SubcutaneousSandoz Canada Incorporated1951-12-31Not applicableCanada
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Papaverine HydrochlorideInjection, solution30 mg/mLIntravenousAmerican Regent1995-09-012017-07-21Us
Papaverine HydrochlorideInjection, solution30 mg/mLIntravenousAmerican Regent1995-09-01Not applicableUs
International/Other Brands
Alapav / Albatran / Artegodan / Cardioverina / Cerebid / Cerespan / Delapav / Dilaves / Dispamil / Drapavel / Durapav / Dynovas / Mesotina / Myobid / Optenyl / Pameion / Pamelon / Panergon / Papacon / Papalease / Papaversan / Papital T.R. / Paptial T.R. / Pavabid / Pavacap / Pavacen / Pavadel / Pavagen / Pavakey / Pavased / Pavatest / Paverolan / Paveron / Pavnell / Qua Bid / Ro-Papav / Therapav / Vasal / Vaso-Pav
Categories
UNII
DAA13NKG2Q
CAS number
58-74-2
Weight
Average: 339.385
Monoisotopic: 339.147058165
Chemical Formula
C20H21NO4
InChI Key
XQYZDYMELSJDRZ-UHFFFAOYSA-N
InChI
InChI=1S/C20H21NO4/c1-22-17-6-5-13(10-18(17)23-2)9-16-15-12-20(25-4)19(24-3)11-14(15)7-8-21-16/h5-8,10-12H,9H2,1-4H3
IUPAC Name
1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxyisoquinoline
SMILES
COC1=C(OC)C=C(CC2=NC=CC3=CC(OC)=C(OC)C=C23)C=C1

Pharmacology

Indication

For the treatment of impotence and vasospasms.

Structured Indications
Not Available
Pharmacodynamics

Papaverine is a nonxanthine phosphodiesterase inhibitor for the relief of cerebral and peripheral ischemia associated with arterial spasm and myocardial ischemia complicated by arrhythmias. The main actions of Papaverine are exerted on cardiac and smooth muscle. Like qathidine, Papaverine acts directly on the heart muscle to depress conduction and prolong the refractory period. Papaverine relaxes various smooth muscles. This relaxation may be prominent if spasm exists. The muscle cell is not paralyzed by Papaverine and still responds to drugs and other stimuli causing contraction. The antispasmodic effect is a direct one, and unrelated to muscle innervation. Papaverine is practically devoid of effects on the central nervous system. Papaverine relaxes the smooth musculature of the larger blood vessels, especially coronary, systemic peripheral, and pulmonary arteries.

Mechanism of action

Perhaps by its direct vasodilating action on cerebral blood vessels, Papaverine increases cerebral blood flow and decreases cerebral vascular resistance in normal subjects; oxygen consumption is unaltered. These effects may explain the benefit reported from the drug in cerebral vascular encephalopathy.

TargetActionsOrganism
AcAMP-specific 3',5'-cyclic phosphodiesterase 4B
inhibitor
Human
UcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A
inhibitor
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding

~90%

Metabolism
Not Available
Route of elimination
Not Available
Half life

0.5-2 hours

Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcebutololThe risk or severity of adverse effects can be increased when Papaverine is combined with Acebutolol.Approved
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Papaverine.Approved
AliskirenThe risk or severity of adverse effects can be increased when Papaverine is combined with Aliskiren.Approved, Investigational
AmifostineThe risk or severity of adverse effects can be increased when Amifostine is combined with Papaverine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Papaverine.Approved
AmiodaroneThe risk or severity of adverse effects can be increased when Amiodarone is combined with Papaverine.Approved, Investigational
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Papaverine.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Papaverine.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Papaverine.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Papaverine is combined with Amyl Nitrite.Approved
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Papaverine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Apraclonidine is combined with Papaverine.Approved
AripiprazoleAripiprazole may increase the hypotensive activities of Papaverine.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Papaverine.Approved, Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Papaverine.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Papaverine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Papaverine is combined with Azilsartan medoxomil.Approved
BarbexacloneBarbexaclone may increase the hypotensive activities of Papaverine.Experimental
BarbitalBarbital may increase the hypotensive activities of Papaverine.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Papaverine.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Papaverine.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Papaverine.Approved
BepridilThe risk or severity of adverse effects can be increased when Bepridil is combined with Papaverine.Approved, Withdrawn
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Papaverine.Approved
BisoprololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Papaverine.Approved
BortezomibThe risk or severity of adverse effects can be increased when Bortezomib is combined with Papaverine.Approved, Investigational
BretyliumThe risk or severity of adverse effects can be increased when Papaverine is combined with Bretylium.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Papaverine.Approved
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Papaverine.Approved, Investigational
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Papaverine.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Papaverine.Approved, Investigational
CanagliflozinThe risk or severity of adverse effects can be increased when Papaverine is combined with Canagliflozin.Approved
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Papaverine.Approved
CaptoprilThe risk or severity of adverse effects can be increased when Papaverine is combined with Captopril.Approved
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Papaverine.Approved
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Papaverine.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Papaverine is combined with Carvedilol.Approved, Investigational
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Papaverine.Approved, Vet Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Papaverine.Approved, Vet Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Papaverine.Approved
CilazaprilThe risk or severity of adverse effects can be increased when Papaverine is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Papaverine.Approved, Investigational
ClevidipineThe risk or severity of adverse effects can be increased when Papaverine is combined with Clevidipine.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Papaverine.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Papaverine.Approved, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Papaverine.Approved
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Papaverine.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Conivaptan is combined with Papaverine.Approved, Investigational
DapagliflozinThe risk or severity of adverse effects can be increased when Papaverine is combined with Dapagliflozin.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Papaverine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Papaverine.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Papaverine is combined with Diclofenamide.Approved
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Papaverine.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Papaverine is combined with Dinutuximab.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Papaverine.Approved
DoxazosinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Papaverine.Approved
DuloxetinePapaverine may increase the orthostatic hypotensive activities of Duloxetine.Approved
EfonidipineThe risk or severity of adverse effects can be increased when Efonidipine is combined with Papaverine.Approved, Investigational
EmpagliflozinThe risk or severity of adverse effects can be increased when Papaverine is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Papaverine.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Papaverine.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Papaverine.Approved
EpoprostenolThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Papaverine.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Papaverine.Approved
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Papaverine.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Papaverine.Approved
FelodipineThe risk or severity of adverse effects can be increased when Felodipine is combined with Papaverine.Approved, Investigational
FenoldopamThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Papaverine.Approved
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Papaverine.Approved, Investigational
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Papaverine.Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Papaverine.Approved, Vet Approved
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Papaverine.Approved, Investigational
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Papaverine.Approved, Vet Approved
HexobarbitalHexobarbital may increase the hypotensive activities of Papaverine.Approved
HydralazineThe risk or severity of adverse effects can be increased when Papaverine is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Papaverine.Approved, Vet Approved
HydroflumethiazideThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Papaverine.Approved, Investigational
IloprostThe risk or severity of adverse effects can be increased when Iloprost is combined with Papaverine.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Papaverine.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Papaverine.Approved
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Papaverine.Approved
IndoraminThe risk or severity of adverse effects can be increased when Indoramin is combined with Papaverine.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Papaverine.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Papaverine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Papaverine.Approved, Vet Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Papaverine.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Papaverine.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Papaverine is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Papaverine.Approved
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Papaverine.Approved
LacidipineThe risk or severity of adverse effects can be increased when Lacidipine is combined with Papaverine.Approved, Investigational
LercanidipineThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Papaverine.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Papaverine is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Papaverine.Approved, Investigational
LevodopaPapaverine may increase the hypotensive activities of Levodopa.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Papaverine.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Papaverine.Approved, Investigational
LofexidineThe risk or severity of adverse effects can be increased when Lofexidine is combined with Papaverine.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Papaverine.Approved
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Papaverine.Approved, Investigational
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Papaverine.Approved
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Papaverine.Approved
MethohexitalMethohexital may increase the hypotensive activities of Papaverine.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Papaverine.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Methyldopa is combined with Papaverine.Approved
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Papaverine.Approved
MetipranololThe risk or severity of adverse effects can be increased when Papaverine is combined with Metipranolol.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Papaverine.Approved
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Papaverine.Approved, Investigational
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Papaverine.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Papaverine.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Papaverine.Approved, Investigational
MoxonidineThe risk or severity of adverse effects can be increased when Moxonidine is combined with Papaverine.Approved, Investigational
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Papaverine.Approved, Investigational
NadololThe risk or severity of adverse effects can be increased when Papaverine is combined with Nadolol.Approved
NebivololThe risk or severity of adverse effects can be increased when Papaverine is combined with Nebivolol.Approved, Investigational
NesiritideThe risk or severity of adverse effects can be increased when Papaverine is combined with Nesiritide.Approved, Investigational
NicardipineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Papaverine.Approved
NicorandilNicorandil may increase the hypotensive activities of Papaverine.Approved, Investigational
NifedipineThe risk or severity of adverse effects can be increased when Papaverine is combined with Nifedipine.Approved
NilvadipineThe risk or severity of adverse effects can be increased when Nilvadipine is combined with Papaverine.Approved, Investigational
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Papaverine.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Papaverine.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Papaverine.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Papaverine.Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Papaverine.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Papaverine.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Papaverine.Approved
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Papaverine.Approved, Investigational
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Papaverine.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Papaverine.Approved, Vet Approved
PenbutololThe risk or severity of adverse effects can be increased when Papaverine is combined with Penbutolol.Approved, Investigational
PentobarbitalPentobarbital may increase the hypotensive activities of Papaverine.Approved, Vet Approved
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Papaverine.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Papaverine.Approved
PhenobarbitalPhenobarbital may increase the hypotensive activities of Papaverine.Approved
PhenoxybenzamineThe risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Papaverine.Approved
PhentolamineThe risk or severity of adverse effects can be increased when Phentolamine is combined with Papaverine.Approved
PindololThe risk or severity of adverse effects can be increased when Pindolol is combined with Papaverine.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Papaverine.Approved, Investigational
PramipexoleThe risk or severity of adverse effects can be increased when Pramipexole is combined with Papaverine.Approved, Investigational
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Papaverine.Approved
PrimidonePrimidone may increase the hypotensive activities of Papaverine.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Papaverine.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Papaverine.Approved, Investigational
QuetiapineThe risk or severity of adverse effects can be increased when Papaverine is combined with Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Papaverine.Approved, Investigational
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Papaverine.Approved
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Papaverine.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Papaverine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Papaverine.Approved, Investigational
RibociclibThe risk or severity of QTc prolongation can be increased when Ribociclib is combined with Papaverine.Approved
RiociguatThe risk or severity of adverse effects can be increased when Papaverine is combined with Riociguat.Approved
RisperidonePapaverine may increase the hypotensive activities of Risperidone.Approved, Investigational
RopiniroleThe risk or severity of adverse effects can be increased when Ropinirole is combined with Papaverine.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Papaverine.Approved
RotigotineThe risk or severity of adverse effects can be increased when Rotigotine is combined with Papaverine.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Papaverine.Approved
SecobarbitalSecobarbital may increase the hypotensive activities of Papaverine.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Papaverine.Approved, Investigational, Vet Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Papaverine.Approved, Vet Approved
Sodium NitriteThe risk or severity of adverse effects can be increased when Sodium Nitrite is combined with Papaverine.Approved
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Papaverine.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Papaverine.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Streptokinase is combined with Papaverine.Approved, Investigational
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Papaverine.Approved, Investigational
TamsulosinThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Papaverine.Approved, Investigational
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Papaverine.Approved, Investigational
TerazosinThe risk or severity of adverse effects can be increased when Papaverine is combined with Terazosin.Approved
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Papaverine.Approved, Investigational, Withdrawn
ThiamylalThiamylal may increase the hypotensive activities of Papaverine.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Papaverine.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Papaverine.Approved, Withdrawn
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Papaverine.Approved
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Papaverine.Approved
TolazolineThe risk or severity of adverse effects can be increased when Tolazoline is combined with Papaverine.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Papaverine.Approved, Withdrawn
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Papaverine.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Papaverine.Approved
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Papaverine.Approved
TretinoinThe risk or severity of adverse effects can be increased when Tretinoin is combined with Papaverine.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Papaverine.Approved
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Papaverine.Approved, Investigational
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Papaverine.Approved
Food Interactions
Not Available

References

General References
  1. Tang Y, Luan J, Zhang X: Accelerating tissue expansion by application of topical papaverine cream. Plast Reconstr Surg. 2004 Oct;114(5):1166-9. [PubMed:15457029]
  2. Liu JK, Couldwell WT: Intra-arterial papaverine infusions for the treatment of cerebral vasospasm induced by aneurysmal subarachnoid hemorrhage. Neurocrit Care. 2005;2(2):124-32. [PubMed:16159054]
  3. Takeuchi K, Sakamoto S, Nagayoshi Y, Nishizawa H, Matsubara J: Reactivity of the human internal thoracic artery to vasodilators in coronary artery bypass grafting. Eur J Cardiothorac Surg. 2004 Nov;26(5):956-9. [PubMed:15519189]
External Links
Human Metabolome Database
HMDB15245
KEGG Drug
D07425
KEGG Compound
C06533
PubChem Compound
4680
PubChem Substance
46508003
ChemSpider
4518
BindingDB
14754
ChEBI
28241
ChEMBL
CHEMBL19224
Therapeutic Targets Database
DAP000959
PharmGKB
PA164745550
HET
EV1
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Papaverine
ATC Codes
G04BE52 — Papaverine, combinationsG04BE02 — PapaverineA03AD01 — Papaverine
AHFS Codes
  • 24:12.92 — Miscellaneous Vasodilatating Agents
PDB Entries
2wey / 3iak
MSDS
Download (74.4 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0Not Yet RecruitingTreatmentProstatic Hyperplasia1
0TerminatedHealth Services ResearchCognitive Deficits / Schizophrenic Disorders1
2CompletedSupportive CareProstate Cancer1
3TerminatedTreatmentGastroenteritis1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Dosage forms
FormRouteStrength
Injection, solutionIntravenous30 mg/mL
LiquidIntramuscular; Intravenous; Subcutaneous65 mg
Prices
Unit descriptionCostUnit
Papaverine 150 mg capsule sa1.86USD capsule
Papaverine 60 mg/2 ml vial1.68USD ml
Papaverine hcl powder0.76USD g
Para-time 150 mg capsule sa0.23USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)226 (dec) °CPhysProp
logP3Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0129 mg/mLALOGPS
logP4.19ALOGPS
logP3.08ChemAxon
logS-4.4ALOGPS
pKa (Strongest Basic)6.03ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area49.81 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity95.52 m3·mol-1ChemAxon
Polarizability36.57 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9911
Blood Brain Barrier+0.9633
Caco-2 permeable+0.8866
P-glycoprotein substrateNon-substrate0.5389
P-glycoprotein inhibitor INon-inhibitor0.6485
P-glycoprotein inhibitor IINon-inhibitor0.8005
Renal organic cation transporterNon-inhibitor0.7229
CYP450 2C9 substrateNon-substrate0.796
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateSubstrate0.6263
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorInhibitor0.8448
CYP450 2C19 inhibitorInhibitor0.778
CYP450 3A4 inhibitorInhibitor0.7959
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8558
Ames testNon AMES toxic0.689
CarcinogenicityNon-carcinogens0.9503
BiodegradationNot ready biodegradable0.9262
Rat acute toxicity2.9877 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9329
hERG inhibition (predictor II)Non-inhibitor0.7274
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - EI-BGC-MSsplash10-0079-4569000000-42d74df972bf1280fb29
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0006-0009000000-376bdab66f9ada8143f2
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0f6x-0049000000-fbf8945b1b40a8e629ff
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-00di-0779000000-37837168aff5cb2db6db
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0006-0019000000-175d5d7601656bade9be
MS/MS Spectrum - , positiveLC-MS/MSsplash10-00dl-0569000000-1f7e7c97dcea64bf274a

Taxonomy

Description
This compound belongs to the class of organic compounds known as benzylisoquinolines. These are organic compounds containing an isoquinoline to which a benzyl group is attached.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Isoquinolines and derivatives
Sub Class
Benzylisoquinolines
Direct Parent
Benzylisoquinolines
Alternative Parents
Dimethoxybenzenes / Phenoxy compounds / Anisoles / Alkyl aryl ethers / Pyridines and derivatives / Heteroaromatic compounds / Azacyclic compounds / Organopnictogen compounds / Organonitrogen compounds / Hydrocarbon derivatives
Substituents
Benzylisoquinoline / O-dimethoxybenzene / Dimethoxybenzene / Phenoxy compound / Anisole / Phenol ether / Methoxybenzene / Alkyl aryl ether / Monocyclic benzene moiety / Pyridine
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
benzylisoquinoline alkaloid, dimethoxybenzene, isoquinolines (CHEBI:28241) / Isoquinoline alkaloids (C06533)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Metal ion binding
Specific Function
Hydrolyzes the second messenger cAMP, which is a key regulator of many important physiological processes. May be involved in mediating central nervous system effects of therapeutic agents ranging f...
Gene Name
PDE4B
Uniprot ID
Q07343
Uniprot Name
cAMP-specific 3',5'-cyclic phosphodiesterase 4B
Molecular Weight
83342.695 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Xin ZC, Kim EK, Lin CS, Liu WJ, Tian L, Yuan YM, Fu J: Effects of icariin on cGMP-specific PDE5 and cAMP-specific PDE4 activities. Asian J Androl. 2003 Mar;5(1):15-8. [PubMed:12646997]
  4. Zhu S, Gan Z, Li Z, Liu Y, Yang X, Deng P, Xie Y, Yu M, Liao H, Zhao Y, Zhao L, Liao F: The measurement of cyclic nucleotide phosphodiesterase 4 activities via the quantification of inorganic phosphate with malachite green. Anal Chim Acta. 2009 Mar 16;636(1):105-10. doi: 10.1016/j.aca.2009.01.035. Epub 2009 Jan 22. [PubMed:19231363]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Metal ion binding
Specific Function
Plays a role in signal transduction by regulating the intracellular concentration of cyclic nucleotides. Can hydrolyze both cAMP and cGMP, but has higher affinity for cAMP and is more efficient wit...
Gene Name
PDE10A
Uniprot ID
Q9Y233
Uniprot Name
cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A
Molecular Weight
88411.71 Da
References
  1. Weber M, Breier M, Ko D, Thangaraj N, Marzan DE, Swerdlow NR: Evaluating the antipsychotic profile of the preferential PDE10A inhibitor, papaverine. Psychopharmacology (Berl). 2009 May;203(4):723-35. doi: 10.1007/s00213-008-1419-x. Epub 2008 Dec 9. [PubMed:19066855]

Drug created on June 13, 2005 07:24 / Updated on December 10, 2017 17:18